companydata.dkcompanydata.dk

DeLiver Pharma ApS: Financial statements 2025

CVR: 39432714

Source: annual report 2025, Danish Business Authority

01/01/2025 – 31/12/2025

DeLiver Pharma ApS (CVR 39432714) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -20,487 and a net result of DKK -31,867 compared with DKK -21,682 the year before. Equity in the 2025 report amounted to DKK 163,221. The solvency ratio was 92.5%.

Gross Profit
DKK -20,487
Profit/Loss
DKK -31,867
Equity
DKK 163,221
Total Assets
DKK 176,363
Employees
0

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2025--20K-32K163K0
2024--10K-22K195K0
2023-119K107K217K0
2022--18K-29K109K-
2021--22K-147K139K-

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is DeLiver Pharma ApS?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2025

DeLiver Pharma ApS: The 2024 annual report is outJun 20, 2025

DeLiver Pharma ApS has published its annual report for 2024. Gross profit came to DKK -10,302, and the net result was DKK -21,682.

About DeLiver Pharma ApS

DeLiver Pharma ApS is a Danish company of the type Anpartsselskab based in Faaborg, founded in 2018. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Niels Jonas Heilskov Graversen. The board consists of Jens Kristian Damsgaard (chair), Holger Jon Møller, Niels Jonas Heilskov Graversen and Søren Kragh Moestrup. The company's owners include MOESTRUP HOLDING 2007 ApS, MØLLER HOLDING 2007 ApS and PHIDEAS ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -20,487 and a net result of DKK -31,867 compared with DKK -21,682 the year before. Equity in the 2025 report amounted to DKK 163,221.

Source: annual report 2025, Danish Business Authority

Other financial years